Skip to main content
Erschienen in: International Journal of Clinical Oncology 5/2016

02.03.2016 | Original Article

Identification of a predictive factor for distant metastasis in esophageal squamous cell carcinoma after definitive chemoradiotherapy

verfasst von: Katsuyuki Sakanaka, Yuichi Ishida, Satoshi Itasaka, Yasumasa Ezoe, Ikuo Aoyama, Shinichi Miyamoto, Takahiro Horimatsu, Manabu Muto, Masahiro Hiraoka

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2016

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

Distant metastasis (DM) after definitive chemoradiotherapy has not been a focus of research in esophageal carcinoma. At present, local–regional control is improving following advances in salvage treatments after definitive chemoradiotherapy. There is a need to focus on suppressing the development of DM. The aim of this study was to identify pre-treatment factors associated with DM after definitive chemoradiotherapy.

Materials and methods

This study included 144 patients with thoracic esophageal squamous cell carcinoma (Stage I/II/III/IV; 35/17/69/23) (TNM 7th) who underwent definitive chemoradiotherapy; >50 Gy was prescribed to all gross tumors with concurrent administration of 5-fluorouracil ± platinum. Pre-treatment factors included age, gender, performance status, tumor location, T/N/M status, tumor length, size of metastatic lymph nodes (LN size), and the presence of intramural metastasis or multiple primary tumors. The effects of pre-treatment factors on overall survival (OS) and DM were evaluated.

Results

The median follow-up period was 48 months. DM occurred as an initial progression in 21 % of patients, and LN size correlated with DM development (hazard ratio [HR] = 5.12; p = 0.0013) and poor OS (HR = 2.20; p = 0.0076) in univariate and multivariate analyses.

Conclusions

LN size is a quantitative pre-treatment prognostic factor that should be assessed prior to definitive chemoradiotherapy. Patients with large metastatic lymph nodes are at high risk of DM and should be monitored.
Literatur
1.
Zurück zum Zitat National Comprehensive Cancer Network (2015) Clinical practice guidelines for treatment of cancer by site (NCCN Guidelines) Esophageal and esophagogastric junction cancers (version 3. 2015) National Comprehensive Cancer Network (2015) Clinical practice guidelines for treatment of cancer by site (NCCN Guidelines) Esophageal and esophagogastric junction cancers (version 3. 2015)
2.
Zurück zum Zitat Cooper JS, Guo MD, Herskovic A et al (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281:1623–1627CrossRefPubMed Cooper JS, Guo MD, Herskovic A et al (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281:1623–1627CrossRefPubMed
3.
Zurück zum Zitat Kato K, Muro K, Minashi K et al (2011) Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II–III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys 81:684–690CrossRefPubMed Kato K, Muro K, Minashi K et al (2011) Phase II study of chemoradiotherapy with 5-fluorouracil and cisplatin for Stage II–III esophageal squamous cell carcinoma: JCOG trial (JCOG 9906). Int J Radiat Oncol Biol Phys 81:684–690CrossRefPubMed
4.
Zurück zum Zitat Nishimura Y, Hiraoka M, Koike R et al (2012) Long-term follow-up of a randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021). Jpn J Clin Oncol 42:807–812CrossRefPubMed Nishimura Y, Hiraoka M, Koike R et al (2012) Long-term follow-up of a randomized phase II study of cisplatin/5-FU concurrent chemoradiotherapy for esophageal cancer (KROSG0101/JROSG021). Jpn J Clin Oncol 42:807–812CrossRefPubMed
5.
Zurück zum Zitat al-Sarraf M, Martz K, Herskovic A et al (1997) Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 15:277–284PubMed al-Sarraf M, Martz K, Herskovic A et al (1997) Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 15:277–284PubMed
6.
Zurück zum Zitat Minsky BD, Pajak TF, Ginsberg RJ et al (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167–1174CrossRefPubMed Minsky BD, Pajak TF, Ginsberg RJ et al (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167–1174CrossRefPubMed
7.
Zurück zum Zitat Kato K, Eguchi Nakajima T, Ito Y et al (2013) Phase II Study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for stage II–III esophageal carcinoma. Jpn J Clin Oncol 43:608–615CrossRefPubMed Kato K, Eguchi Nakajima T, Ito Y et al (2013) Phase II Study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for stage II–III esophageal carcinoma. Jpn J Clin Oncol 43:608–615CrossRefPubMed
8.
Zurück zum Zitat Yano T, Muto M, Minashi K et al (2012) Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: a phase II study. Int J Cancer 131:1228–1234CrossRefPubMed Yano T, Muto M, Minashi K et al (2012) Photodynamic therapy as salvage treatment for local failure after chemoradiotherapy in patients with esophageal squamous cell carcinoma: a phase II study. Int J Cancer 131:1228–1234CrossRefPubMed
9.
Zurück zum Zitat Markar S, Gronnier C, Duhamel A et al (2015) Salvage surgery after chemoradiotherapy in the management of esophageal cancer: is it a viable therapeutic option? J Clin Oncol 33:3866–3873CrossRefPubMed Markar S, Gronnier C, Duhamel A et al (2015) Salvage surgery after chemoradiotherapy in the management of esophageal cancer: is it a viable therapeutic option? J Clin Oncol 33:3866–3873CrossRefPubMed
10.
Zurück zum Zitat Yano T, Muto M, Hattori S et al (2008) Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy 40:717–721CrossRefPubMed Yano T, Muto M, Hattori S et al (2008) Long-term results of salvage endoscopic mucosal resection in patients with local failure after definitive chemoradiotherapy for esophageal squamous cell carcinoma. Endoscopy 40:717–721CrossRefPubMed
11.
Zurück zum Zitat Sobin LH, Gospodarowicz M, Wittekind C (2009) TNM Classification of malignant tumours, 7th edn. Wiley-Blackwell, New York Sobin LH, Gospodarowicz M, Wittekind C (2009) TNM Classification of malignant tumours, 7th edn. Wiley-Blackwell, New York
12.
Zurück zum Zitat Kato H, Sato A, Fukuda H et al (2009) A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol 39:638–643CrossRefPubMed Kato H, Sato A, Fukuda H et al (2009) A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol 39:638–643CrossRefPubMed
13.
Zurück zum Zitat Shinoda M, Ando N, Kato K et al (2015) Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci 106:407–412CrossRefPubMedPubMedCentral Shinoda M, Ando N, Kato K et al (2015) Randomized study of low-dose versus standard-dose chemoradiotherapy for unresectable esophageal squamous cell carcinoma (JCOG0303). Cancer Sci 106:407–412CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Kato K, Muro K, Ando N et al (2014) A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: the Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI). Esophagus 11:183–188CrossRef Kato K, Muro K, Ando N et al (2014) A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: the Japan Clinical Oncology Group (JCOG) Trial (JCOG 9905-DI). Esophagus 11:183–188CrossRef
15.
Zurück zum Zitat Mizowaki T, Nishimura Y, Shimada Y et al (1996) Optimal size criteria of malignant lymph nodes in the treatment planning of radiotherapy for esophageal cancer: evaluation by computed tomography and magnetic resonance imaging. Int J Radiat Oncol Biol Phys 36:1091–1098CrossRefPubMed Mizowaki T, Nishimura Y, Shimada Y et al (1996) Optimal size criteria of malignant lymph nodes in the treatment planning of radiotherapy for esophageal cancer: evaluation by computed tomography and magnetic resonance imaging. Int J Radiat Oncol Biol Phys 36:1091–1098CrossRefPubMed
16.
Zurück zum Zitat Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRef Gray RJ (1988) A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141–1154CrossRef
17.
Zurück zum Zitat Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRef Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRef
18.
Zurück zum Zitat Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458CrossRefPubMed Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458CrossRefPubMed
19.
Zurück zum Zitat Dhar DK, Hattori S, Tonomoto Y et al (2007) Appraisal of a revised lymph node classification system for esophageal squamous cell cancer. Ann Thorac Surg 83:1265–1272CrossRefPubMed Dhar DK, Hattori S, Tonomoto Y et al (2007) Appraisal of a revised lymph node classification system for esophageal squamous cell cancer. Ann Thorac Surg 83:1265–1272CrossRefPubMed
20.
Zurück zum Zitat Nomura M, Shitara K, Kodaira T et al (2012) Recursive partitioning analysis for new classification of patients with esophageal cancer treated by chemoradiotherapy. Int J Radiat Oncol Biol Phys 84:786–792CrossRefPubMed Nomura M, Shitara K, Kodaira T et al (2012) Recursive partitioning analysis for new classification of patients with esophageal cancer treated by chemoradiotherapy. Int J Radiat Oncol Biol Phys 84:786–792CrossRefPubMed
21.
Zurück zum Zitat Don DM, Anzai Y, Lufkin RB et al (1995) Evaluation of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Laryngoscope 105:669–674CrossRefPubMed Don DM, Anzai Y, Lufkin RB et al (1995) Evaluation of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Laryngoscope 105:669–674CrossRefPubMed
22.
Zurück zum Zitat Wind J, Lagarde SM, Ten Kate FJ et al (2007) A systematic review on the significance of extracapsular lymph node involvement in gastrointestinal malignancies. Eur J Surg Oncol 33:401–408CrossRefPubMed Wind J, Lagarde SM, Ten Kate FJ et al (2007) A systematic review on the significance of extracapsular lymph node involvement in gastrointestinal malignancies. Eur J Surg Oncol 33:401–408CrossRefPubMed
23.
Zurück zum Zitat Rice TW, Rusch VW, Ishwaran H et al (2010) Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American joint committee on cancer/international union against cancer cancer staging manuals. Cancer 116:3763–3773CrossRefPubMed Rice TW, Rusch VW, Ishwaran H et al (2010) Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American joint committee on cancer/international union against cancer cancer staging manuals. Cancer 116:3763–3773CrossRefPubMed
24.
25.
Zurück zum Zitat Shi W, Wang W, Wang J et al (2013) Meta-analysis of 18FDG PET-CT for nodal staging in patients with esophageal cancer. Surg Oncol 22:112–116CrossRefPubMed Shi W, Wang W, Wang J et al (2013) Meta-analysis of 18FDG PET-CT for nodal staging in patients with esophageal cancer. Surg Oncol 22:112–116CrossRefPubMed
26.
Zurück zum Zitat Herskovic A, Martz K, al-Sarraf M et al (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326:1593–1598CrossRefPubMed Herskovic A, Martz K, al-Sarraf M et al (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326:1593–1598CrossRefPubMed
27.
Zurück zum Zitat Bentzen SM, Thames HD (1996) Tumor volume and local control probability: clinical data and radiobiological interpretations. Int J Radiat Oncol Biol Phys 36:247–251CrossRefPubMed Bentzen SM, Thames HD (1996) Tumor volume and local control probability: clinical data and radiobiological interpretations. Int J Radiat Oncol Biol Phys 36:247–251CrossRefPubMed
28.
Zurück zum Zitat Ishida K, Ando N, Yamamoto S et al (2004) Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group Trial (JCOG9516). Jpn J Clin Oncol 34:615–619CrossRefPubMed Ishida K, Ando N, Yamamoto S et al (2004) Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group Trial (JCOG9516). Jpn J Clin Oncol 34:615–619CrossRefPubMed
29.
Zurück zum Zitat Crosby T, Hurt CN, Falk S et al (2013) Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol 14:627–637CrossRefPubMed Crosby T, Hurt CN, Falk S et al (2013) Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. Lancet Oncol 14:627–637CrossRefPubMed
30.
Zurück zum Zitat Conroy T, Galais MP, Raoul JL et al (2014) Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 15:305–314CrossRefPubMed Conroy T, Galais MP, Raoul JL et al (2014) Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 15:305–314CrossRefPubMed
31.
Zurück zum Zitat Welsh J, Gomez D, Palmer MB et al (2011) Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys 81:1336–1342CrossRefPubMedPubMedCentral Welsh J, Gomez D, Palmer MB et al (2011) Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys 81:1336–1342CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Welsh J, Palmer MB, Ajani JA et al (2012) Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys 82:468–474CrossRefPubMed Welsh J, Palmer MB, Ajani JA et al (2012) Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys 82:468–474CrossRefPubMed
33.
Zurück zum Zitat Welsh J, Settle SH, Amini A et al (2012) Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 118:2632–2640CrossRefPubMed Welsh J, Settle SH, Amini A et al (2012) Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 118:2632–2640CrossRefPubMed
Metadaten
Titel
Identification of a predictive factor for distant metastasis in esophageal squamous cell carcinoma after definitive chemoradiotherapy
verfasst von
Katsuyuki Sakanaka
Yuichi Ishida
Satoshi Itasaka
Yasumasa Ezoe
Ikuo Aoyama
Shinichi Miyamoto
Takahiro Horimatsu
Manabu Muto
Masahiro Hiraoka
Publikationsdatum
02.03.2016
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 5/2016
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-0967-z

Weitere Artikel der Ausgabe 5/2016

International Journal of Clinical Oncology 5/2016 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.